Passage Bio to Participate in 2020 Virtual Cell & Gene Meeting on the Mesa
October 06 2020 - 7:00AM
Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company
focused on developing transformative therapies for rare, monogenic
central nervous system disorders, today announced that management
will participate in the virtual 2020 Cell & Gene Meeting on the
Mesa, October 12-16, 2020.
Passage Bio’s Chief Operating Officer, Jill M. Quigley, J.D.,
will deliver an overview of the company as part of the 2020 company
presentations segment of the conference. Passage Bio’s company
presentation will be available to view on-demand throughout the
entirety of the conference.
Additionally, Alex Fotopoulos, Chief Technical Officer of
Passage Bio, will participate in the panel discussion titled,
“Accelerating Biotherapeutics Development and Production for
Increased Market Impact of Life Saving Therapeutics,” moderated by
Susan D’Costa, Ph.D., Senior Director, Technical Program Design,
Viral Vector Services, Thermo Fisher Scientific. The session will
cover key topics such as integrated vs. modular manufacturing
approaches, ensuring security of supply, proactive approaches to
regulatory compliance, and ultimately, the panel’s vision for the
future. The panel session will be available on-demand to attendees
as of Monday, October 12, 2020.
Organized by the Alliance for Regenerative Medicine, the Cell
& Gene Meeting on the Mesa is a five-day virtual conference
featuring more than 120 dedicated company presentations by leading
public and private companies, highlighting technical and clinical
achievements over the past 12 months in the areas of cell therapy,
gene therapy, gene editing, tissue engineering, and broader
regenerative medicine technologies. The meeting also includes over
100 panelists and featured speakers taking part in 20 in-depth
sessions covering all aspects of cell and gene therapy
commercialization.
Please visit www.meetingonthemesa.com for full information
including registration. Complimentary attendance at this event is
available for credentialed investors and members of the media only.
Investors should contact Laura Stringham at
lstringham@alliancerm.org and interested media should contact
Kaitlyn Dupont at kdupont@alliancerm.org.
About Passage BioPassage Bio is a genetic
medicines company focused on developing transformative therapies
for rare, monogenic central nervous system disorders with limited
or no approved treatment options. The company is based in
Philadelphia, PA and has a research, collaboration and license
agreement with the University of Pennsylvania and its Gene Therapy
Program (GTP). The GTP conducts discovery and IND-enabling
preclinical work and Passage Bio conducts all clinical development,
regulatory strategy and commercialization activities under the
agreement. The company has a development portfolio of six product
candidates, with the option to license eleven more, with lead
programs in GM1 gangliosidosis, frontotemporal dementia and Krabbe
disease.
For further information, please contact:
Investors:Sarah McCabe and Zofia MitaStern Investor Relations,
Inc.sarah.mccabe@sternir.com zofia.mita@sternir.com
Media:Gwen FisherPassage
Bio215.407.1548gfisher@passagebio.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Jul 2024 to Aug 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Aug 2023 to Aug 2024